Меню
Идёт набор NCT07290153

Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC

— Наблюдательное Breast Cancer Female NOS General Anxiety Disorder Depressive Disorder

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Breast Cancer Female NOS, General Anxiety Disorder, Depressive Disorder. Базовые параметры: 18 лет — 70 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Prospective Observational Study of Psychological State, Immunotherapy Response, and Multi-Omics Features in Triple-Negative Breast Cancer

Обзор

This study aims to evaluate whether psychological status affects the response to neoadjuvant immunotherapy in triple-negative breast cancer (TNBC) and how it relates to immune changes during treatment. Participants will receive standard therapy, undergo psychological assessments, and provide blood and saliva samples for biomarker testing. By linking psychological status with immune profiles and treatment outcomes, the study seeks to clarify how mental state may influence immunotherapy effectiveness.

Подробное описание

The goal of this prospective observational study is to understand how psychological status influences the therapeutic response and long-term outcomes of patients with triple-negative breast cancer (TNBC) receiving neoadjuvant immunotherapy. The study primarily focuses on the association between psychological status and pathological complete response (pCR) as well as event-free survival (EFS).

In this study, early-stage TNBC patients undergoing standard neoadjuvant immunotherapy will complete psychological assessments at baseline and multiple timepoints during treatment. Measurement include self-assessment questionnaires like GAD-7 and PHQ-9 and clinician-administered depression assessment scale like Hamilton Depression Rating Scale (HDRS). Blood and saliva samples will be collected to measure immune cell subsets, inflammatory cytokines, cortisol, and heart rate variability (HRV). Treatment response (pCR, ORR) and long-term outcomes (EFS) will be recorded and analyzed. By integrating psychological measures, circulating immune markers, and clinical efficacy endpoints, researchers aim to build a psychological-immune-response association model and identify psychophysiological biomarkers that may predict immunotherapy benefit.

Первичные конечные точки

  • Pathological Complete Response (pCR) Rate [Срок оценки: At the time of definitive surgery]
  • Event-Free Survival (EFS) [Срок оценки: 18 Months]
Вторичные конечные точки (3)
  • Objective Response Rate (ORR) [Срок оценки: 18 Months]
  • Correlation Between Psychological Status-Related Blood Biomarkers and Treatment Response [Срок оценки: 18 Months]
  • Quality of Life and Emotional Trajectory During Treatment [Срок оценки: 18 Months]

Критерии участия

Inclusion Criteria：

Participants must meet all of the following criteria:

  • Age ≥ 18 years;
  • Female patients;
  • Voluntarily agrees to participate in the study and signs the informed consent form, with good compliance and willingness to complete follow-up assessments;
  • Histologically confirmed invasive triple-negative breast cancer (TNBC), defined as ER < 1%, PR < 1%, and HER-2 0-1+ by IHC, or HER-2 2+ with negative FISH/CISH results (no gene amplification);
  • Planned to receive neoadjuvant immunotherapy-based treatment as part of routine clinical care.

Критерии исключения

Patients will be excluded if any of the following conditions apply:

  • Presence of distant metastasis;
  • History of other malignancies, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or cancers with no evidence of disease for ≥ 5 years;
  • Participation in another clinical trial and receipt of an investigational drug or treatment within 30 days before initiation of neoadjuvant therapy;
  • Known immunodeficiency or HIV infection;
  • Severe cardiac, pulmonary, hepatic, or renal dysfunction;
  • Uncontrolled infection or active systemic infection;
  • Pregnancy or breastfeeding;
  • Severe psychological or cognitive impairment that precludes completion of psychological assessments.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Китай · 1 центр
  • Fudan University Shangahi Cancer Center — Шанхай

Идентификаторы

NCT: NCT07290153 · SCHBCC-N0105

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗